Costes Nadine, Elomri Abdelhakim, Dufat Hanh, Michel Sylvie, Seguin Elisabeth, Koch Michel, Tillequin François, Pfeiffer Bruno, Renard Pierre, Léonce Stéphane, Pierré Alain
Laboratoire de Pharmacognosie de l'Université René Descartes, UMR/CNRS No. 8638, Faculté des Sciences Pharmaceutiques et Biologiques, 4, Avenue de l'Observatoire, F-75006 Paris, France.
Oncol Res. 2003;13(4):191-7.
The novel 6-dialkylaminoalkylamino-3,3,12-trimethyl-3,12-dihydro-7H-pyrano[2,3-c]acridine-7-ones 5-11 and their benzo [b]pyrano[2,3-h]acridine-7-one counterparts 12-18 were prepared by treatment of acronycine (1) or benzo[b]acronycine (4) with an excess of the appropriate dialkylaminoalkylamine. In both series, the introduction of a dialkylaminoalkylamino side chain at position 6 resulted in a significant increase of the cytotoxic activity against L1210 cells when compared with the parent compounds bearing a methoxy group, accompanied with an increased potency to arrest cells in the G2 + M phases of the cell cycle.
通过用过量的合适二烷基氨基烷基胺处理吖啶酮(1)或苯并[b]吖啶酮(4),制备了新型的6-二烷基氨基烷基氨基-3,3,12-三甲基-3,12-二氢-7H-吡喃并[2,3-c]吖啶-7-酮5-11及其苯并[b]吡喃并[2,3-h]吖啶-7-酮类似物12-18。在这两个系列中,与带有甲氧基的母体化合物相比,在6位引入二烷基氨基烷基氨基侧链导致对L1210细胞的细胞毒性活性显著增加,同时使细胞周期阻滞在G2 + M期的效力增强。